Xinhuanet: Chengdu’s Talent Appeal Spurs the City’s Embrace of the World
“Chengdu is increasingly attracting skilled talent and entrepreneurs to integrate, put down roots, and start businesses in the city. The city continues to become more appealing, which in turn further promotes its international development,” said Xu Wen, head of Southwestern business at PwC’s Chengdu branch.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201125005704/en/
Xu Wen, head of Southwestern business at PwC’s Chengdu branch, takes a media interview (Photo: Business Wire)
In the “City of Opportunity 2020” report released by PwC this year, Chengdu ranked 5th in China, only surpassed by Beijing, Shanghai, Guangzhou, and Shenzhen. Xu sees Chengdu’s great advantage as a “new first-tier” city reflected in the city’s appeal to skilled talent. “With China’s economy undergoing transformation and upgrading, innovation capabilities are becoming more and more important. In this context, cultivating developmental advantages is a crucial issue for any city, which means attracting the best talent.”
“Chengdu is very livable and can attract a large pool of skilled workers, as well as their family and friends,” said Xu. “In addition, the city’s development has taken it far beyond traditional modes and culture. Chengdu is now very international and diverse, which has helped attract more global talent, which in turn has further propelled the city’s international development,” he added.
Xu continued, “More importantly, Chengdu adopts a relatively tolerant approach to regulating various industries, striving to maintain new sectors within the scope of legal and business compliance so they can develop healthily. This makes it easier to introduce innovation and continue to attract talent.”
Chengdu now benchmarks itself against the world’s top cities as it strives for a leading position in the network of global cities. As early as 2013, when Xu’s visit to Chengdu coincided with the Global Fortune Forum held there, he was impressed by the level of internationalization.
In Xu’s view, local government support for industry is key to attracting talent. For example, Xu explained, “PwC’s business in Chengdu is located in Wuhou District, which has given us a lot of support and assistance. Since we established in Wuhou, the district government has also become one of our main service partners. This has helped us build trust and relationships with the government, and meanwhile, the government has implemented our advice effectively. This healthy public-private cooperation has benefitted both parties is an incredibly positive development.”
The Chengdu-based development of PwC bears witness to the city’s deepening integration with the outside world. “With the help of PwC’s client network, we have been able to assist local small and medium-sized enterprises to access financial support, as well as new markets, products, and technologies. We strongly recognize how Chengdu provides fertile soil for innovation,” said Xu.
Looking to the future, Xu believes strongly in development prospects for PwC and the city itself: “Chengdu is in a phase of rapid growth, and we are confident PwC can match that while helping promote development, such as supporting the city to train international professionals. Chengdu continues to grow more attractive to talent, and this will spur its international development.”
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Servier announce updated overall survival results of exploratory TASCO1 phase II study of LONSURF ® + bevacizumab in a first-line setting for patients with unresectable mCRC non-eligible for intensive therapy16.1.2021 22:15:00 CET | Press release
Servier announced today updated results from the exploratory phase II TASCO1 study evaluating LONSURF® (trifluridine/tipiracil) + bevacizumab and capecitabine + bevacizumab (C-B) in a first-line setting for patients with unresectable metastatic colorectal cancer (mCRC) who are non-eligible for intensive therapy.1 The data were announced today during an oral presentation at the 2021 ASCO Gastrointestinal Cancers Symposium (ASCO-GI). Patients with mCRC who are not eligible for chemotherapy face a large unmet need, with fewer treatment options available to them and lower survival rates. Colorectal cancer (CRC) makes up 9.7% of total global cancer cases, with almost 1.4 million new cases of CRC each year.2 In Europe, CRC is the second most common cause of death due to cancer, and those with a metastatic disease have a 5-year survival rate of just 11%.3 “For patients with metastatic colorectal cancer, those non-eligible for standard combination therapy have few options left and we are conti
H.I.G. Realty Invests in Production Studios & Content Hub in Madrid15.1.2021 09:00:00 CET | Press release
H.I.G. Capital, LLC ("H.I.G."), a leading global alternative investment firm with $43 billion of equity capital under management, announced today that one of its affiliates has invested in Madrid Content City, an approximately 140,000 square meter hub with state of the art audio-visual facilities, including production studios, production & post-production technical facilities, and a university focused on media studies. H.I.G. continues to add to its sizeable portfolio of real estate assets across Europe, consisting of both equity as well as debt investments, with a particular focus on its target market of value-added small and midcap opportunities. Riccardo Dallolio, Managing Director and Head of H.I.G. Europe Realty Partners, commented: “Madrid Content City will benefit from strong secular tailwinds underpinned by the boom in content production. The state-of-the-art studios and related facilities, the exceptional multinational tenant line-up with long term leases, and its critical mas
Eurofins, the global leader in analytical testing, expands worldwide face mask testing & certification capabilities15.1.2021 07:30:00 CET | Press release
Since the start of the pandemic Eurofins (Paris:ERF) has tested thousands of models of surgical and hygienic masks and provided best-in-class speed and certification for PPEs globally, enabling these critical products to get market as fast as possible. Eurofins has developed global leading testing capabilities and certification services in the North America, Europe and Asia ensuring that PPE manufacturers are able to provide the indispensable support needed in the fight against the coronavirus. As of today, Eurofins is one of the few GLP certified and ISO/IEC 17025 accredited laboratory networks to fully cover all testing requirements for surgical/medical and hygienic masks by the FDA, EU regulations and many international and country-specific directives and guidelines such as CEN, CE Marking, ISO, ASTM or OECD. Our robust portfolio for masks includes globally accepted, safety and performance testing, virucidal, bacterial filtration, particle filtration, differential pressure, biocompa
TOXINS 2021: New analyses of pivotal Phase III trial data highlight long duration of response for Dysport ® (abobotulinumtoxinA) in five therapeutic indications15.1.2021 07:00:00 CET | Press release
Regulatory News: Ipsen (Euronext: IPN; ADR: IPSEY) announced results from new analyses of pivotal Phase III clinical trial data to assess treatment intervals over repeat cycles of Dysport® (abobotulinumtoxinA [aboBoNT-A]) in five patient populations. AbobotulinumtoxinA: Evidence for Long Duration of Response from 5 Patient Populations is being shared during the TOXINS 2021 conference, which is taking place virtually between 16-17 January 2020 and is organized by the International Neurotoxin Association.1-28 Ipsen is sharing 26 abstracts during the congress, with data including updates from the recently published surveys into the experience of patients and caregivers, data from the Phase IV ULIS-III trial, and ten abstracts focused on basic science research into neurotoxins.1-27 Spasticity is one of the most common and disabling conditions associated with many neurological conditions in adults and is characterized by velocity-dependent muscle hypertonia. Spasticity can lead to disabilit
Velodyne Lidar Commends NHTSA Plan to Update NCAP14.1.2021 21:58:00 CET | Press release
Velodyne Lidar, Inc. (Nasdaq: VLDR, VLDRW) today commended the U.S. Department of Transportation’s National Highway Traffic Safety Administration (NHTSA) plan to update to its New Car Assessment Program (NCAP). The NHTSA proposal would add four advanced driver assistance system (ADAS) capabilities to the NCAP, keeping pace with evolving safety technologies and providing much-needed information to consumers. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210114005992/en/ Images show vehicle with lidar-based PAEB stopping before adult target @ 50% overlap (above) and vehicle with camera and radar-based PAEB crashing into adult target (below). (Photo: Velodyne Lidar, Inc.) NCAP is the U.S. Government’s premier consumer information program for evaluating vehicle safety performance. The NHTSA proposal to add ADAS technologies to the NCAP includes pedestrian automatic emergency braking, lane keeping support, blind spot warning and
Snow Software Recognized as a 2020 Gartner Peer Insights Customers’ Choice for Software Asset Management14.1.2021 20:39:00 CET | Press release
Snow Software, the global leader in technology intelligence, today announced that the company was named a December 2020 Gartner Peer Insights Customers’ Choice for Software Asset Management (SAM) Tools. Gartner defines software asset management tools as technology that “automates many of the tasks required to maintain compliance with software licenses, thereby controlling software spending.” This is the fourth Gartner Peer Insights Customers’ Choice announcement for SAM, and Snow has earned the distinction all four times. Based solely on feedback from verified customers, Gartner Peer Insights Customers’ Choice reflects reviews and ratings published within the last 12 months. Snow received 100 reviews – the most of any vendor in the market – with an overall rating of 4.6 out of 5 as of January 12, 2021. Earlier this year, Snow was recognized as a Leader in Gartner’s 2020 Magic Quadrant for Software Asset Management Tools1 and received the highest scores in three out of four use cases in
Veristat Supported Marketing Applications for 10% of All FDA Novel Drug Approvals in 202014.1.2021 19:15:00 CET | Press release
Veristat, a scientific-minded global clinical research organization (CRO), announced today that they supported the marketing applications for 10% of the 2020 US Food and Drug Administration (FDA) novel drug approvals. The FDA approved 53 novel drugs, defined by the FDA as New Molecular Entities (NMEs)i, and Veristat regulatory, statistical, and medical writing experts were integral in preparing five of these NME New Drug Applications. Veristat also prepared NDA/BLAs for three non-NME FDA approvals and one Marketing Authorization Application (MAA) that received approval in Europe. "Despite the global challenges in 2020, Veristat continued to advance its mission of helping clients achieve regulatory approval of novel medical therapies," stated Patrick Flanagan, Chief Executive Officer at Veristat. "Now, more than ever, Veristat is focused on providing expert guidance to facilitate the rapid approval for therapies that improve the lives of patients and their families around the world." Ve
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom